Abstract
The nucleoside reverse transcriptase inhibitors (NRTIs), used for treatment of the human immunodeficiency virus-1, compromise mitochondria in cardiomyocytes and other host cells, limiting the clinical use of these drugs. To explore underlying mechanisms, we overexpressed PGC-1α, a master regulator of mitochondrial biogenesis, twofold in H9c2 rat cardiomyocyte cultures, hypothesizing that this might protect the mitochondria from damage induced by the NRTI combination zidovudine (AZT) and didanosine (ddI). The experimental groups, evaluated during 16 passages (P) of drug exposure, included: PGC-1α-overexpressing cells with no exposure, or exposure to 50 µM AZT plus 50 µM ddI; and control cells with no exposure or exposure to the same doses of AZT and ddI. The AZT/ddI combination caused a growth inhibition of 15–20 % in control cells, but none in PGC-1α cells. Apoptosis was highest in AZT/ddI-exposed control cells, and PGC-1α overexpression protected cells from AZT/ddI-induced apoptosis. At P3, P6, P8, and P12, uncoupled mitochondrial oxygen consumption rate, determined by Seahorse 24 XF Analyzer, as higher in AZT/ddI-exposed PGC-1α cells, compared to AZT/ddI-exposed control cells (p < 0.05 at all P). Complex I activity was higher in AZT/ddI-exposed PGC-1α overexpressing cells than that in AZT/ddI-exposed control cells (p < 0.05), and reactive oxygen species levels were lower in PGC-1α overexpressing cells than that in control cells (p < 0.05) when both were exposed to AZT/ddI. Taken together, these experiments show proof of concept that overexpression of PGC-1α protects cardiomyocytes from NRTI-induced toxicity, and suggest that a pharmaceutical agent with similar activity may protect against NRTI-induced mitochondrial toxicity.
Similar content being viewed by others
Abbreviations
- AZT:
-
Zidovudine, 3′-azido-3′-deoxythymidine
- ddI:
-
Didanosine, 2′, 3′-dideoxyinosine
- DCFH:
-
Dichlorofluorescin diacetate
- FCCP:
-
Carbonyl cyanide p-trifluoromethoxy-phenylhydroazone
- HIV-1:
-
Human immunodeficiency virus 1
- NRTI:
-
Nucleoside reverse transcriptase inhibitor
- OCR:
-
Oxygen consumption rate
- OLIGO:
-
Oligomycin
- OXPHOS:
-
Oxidative phosphorylation
- PARP:
-
Poly (ADP-ribose) polymerase
- PBS:
-
Phosphate-buffered saline
- PGC-1α:
-
Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha
- ROS:
-
Reactive oxygen species
- ROT:
-
Rotenone
References
Wallace, K. B. (2008). Mitochondria off target of drug therapy. Trends in Pharmacological Sciences, 29, 361–366.
Blanche, S., Tardieu, M., Benhammou, V., Warszawski, J., & Rustin, P. (2006). Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS, 20, 1685–1690.
Blanche, S., Tardieu, M., Rustin, P., Slama, A., Barret, B., Firtion, G., et al. (1999). Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet, 354, 1084–1089.
Koczor, C. A., & Lewis, W. (2010). Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert opinion on drug metabolism & toxicology, 6, 1493–1504.
Lewis, W. (2005). Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy. Antiviral Therapy, 10(Suppl 2), M13–M27.
Kohler, J. J., & Lewis, W. (2007). A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environmental and Molecular Mutagenesis, 48, 166–172.
Poirier, M. C., Olivero, O. A., Walker, D. M., & Walker, V. E. (2004). Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicology and Applied Pharmacology, 199, 151–161.
Anderson, P. L., Kakuda, T. N., & Lichtenstein, K. A. (2004). The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clinical Infectious Diseases, 38, 743–753.
Lewis, W., Copeland, W. C., & Day, B. J. (2001). Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Laboratory Investigation, 81, 777–790.
Lewis, W., Day, B. J., & Copeland, W. C. (2003). Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nature Reviews Drug Discovery, 2, 812–822.
Leone, T. C., & Kelly, D. P. (2011). Transcriptional control of cardiac fuel metabolism and mitochondrial function. Cold Spring Harbor Symposia on Quantitative Biology, 76, 175–182.
Scarpulla, R. C. (2008). Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiological Reviews, 88, 611–638.
Aggeli, I. K., Beis, I., & Gaitanaki, C. (2008). Oxidative stress and calpain inhibition induce alpha B-crystallin phosphorylation via p38-MAPK and calcium signalling pathways in H9c2 cells. Cellular Signalling, 20, 1292–1302.
Liu, Y., Borchert, G. L., Surazynski, A., & Phang, J. M. (2008). Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene, 27, 6729–6737.
Liu, Y., Nguyen, P., Baris, T. Z., & Poirier, M. C. (2012). Molecular analysis of mitochondrial compromise in rodent cardiomyocytes exposed long term to nucleoside reverse transcriptase inhibitors (NRTIs). Cardiovascular Toxicology, 12, 123–134.
Lu, Z., Xu, X., Hu, X., Fassett, J., Zhu, G., Tao, Y., et al. (2010). PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxidants & Redox Signaling, 13, 1011–1022.
Schilling, J., & Kelly, D. P. (2011). The PGC-1 cascade as a therapeutic target for heart failure. Journal of Molecular and Cellular Cardiology, 51, 578–583.
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jager, S., et al. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397–408.
Rasbach, K. A., & Schnellmann, R. G. (2007). Signaling of mitochondrial biogenesis following oxidant injury. Journal of Biological Chemistry, 282, 2355–2362.
Rowe, G. C., Jiang, A., & Arany, Z. (2010). PGC-1 coactivators in cardiac development and disease. Circulation Research, 107, 825–838.
Schon, E. A., DiMauro, S., Hirano, M., & Gilkerson, R. W. (2010). Therapeutic prospects for mitochondrial disease. Trends in Molecular Medicine, 16, 268–276.
Lai, L., Leone, T. C., Zechner, C., Schaeffer, P. J., Kelly, S. M., Flanagan, D. P., et al. (2008). Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. Genes & Development, 22, 1948–1961.
Lehman, J. J., Barger, P. M., Kovacs, A., Saffitz, J. E., Medeiros, D. M., & Kelly, D. P. (2000). Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. The Journal of Clinical Investigation, 106, 847–856.
Lehman, J. J., & Kelly, D. P. (2002). Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Failure Reviews, 7, 175–185.
Sihag, S., Cresci, S., Li, A. Y., Sucharov, C. C., & Lehman, J. J. (2009). PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. Journal of Molecular and Cellular Cardiology, 46, 201–212.
Lee, H. C., & Wei, Y. H. (2005). Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. International Journal of Biochemistry & Cell Biology, 37, 822–834.
Dam, A. D., Mitchell, A. S., & Quadrilatero, J. (2013). Induction of mitochondrial biogenesis protects against caspase-dependent and caspase-independent apoptosis in L6 myoblasts. Biochimica et Biophysica Acta, 1833, 3426–3435.
Patten, I. S., & Arany, Z. (2012). PGC-1 coactivators in the cardiovascular system. Trends in Endocrinology and Metabolism: TEM, 23, 90–97.
Liu, Y., Shim, E., Nguyen, P., Gibbons, A. T., Mitchell, J. B., & Poirier, M. C. (2014). Tempol protects cardiomyocytes from nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Toxicological Sciences, 139, 133–141.
Bastin, J., Aubey, F., Rotig, A., Munnich, A., & Djouadi, F. (2008). Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients’ cell lacking its components. Journal of Clinical Endocrinology and Metabolism, 93, 1433–1441.
Hondares, E., Mora, O., Yubero, P., de la Concepcion, M. R., Iglesias, R., Giralt, M., et al. (2006). Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation. Endocrinology, 147, 2829–2838.
Johri, A., Calingasan, N. Y., Hennessey, T. M., Sharma, A., Yang, L., Wille, E., et al. (2012). Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington’s disease. Human Molecular Genetics, 21, 1124–1137.
Acknowledgments
This study was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US Government. We wish to thank Alexandra Michalowski for statistical support.
Conflict of interest
The authors declare that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, Y., Shim, E., Crespo-Mejias, Y. et al. Cardiomyocytes are Protected from Antiretroviral Nucleoside Analog-Induced Mitochondrial Toxicity by Overexpression of PGC-1α. Cardiovasc Toxicol 15, 224–231 (2015). https://doi.org/10.1007/s12012-014-9288-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-014-9288-5